Acute%20coronary%20syndromes%20w_out%20persistent%20st-segment%20elevation Treatment

Treatment

Supportive Therapy

Bed Rest

Usually prescribed initially in patients with UA/NSTEMI while ischemia is ongoing
- Patient can be mobilized to bedside commode or chair when symptom-free
Ambulation as tolerated may begin once patient has been hemodynamically stable without recurrent symptoms for 12-24 hours
- Subsequent activity should not be inappropriately restricted
- Focus should be on the prevention of recurrent symptoms and activity may be increased once patient responds to therapy

Supplemental O₂

Give supplemental O₂ to all patients with overt pulmonary congestion or arterial O₂ saturation <90% or respiratory distress or other high-risk features of hypoxemia
Consider in all patients with ACS for the 1st 6 hours of therapy

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

Elvira Manzano, 04 Oct 2022

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

Ticagrelor benefits in TWILIGHT hold up in diabetes

Roshini Claire Anthony, 23 Apr 2020

Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.

HK in CKD: Do diet, HD frequency matter?

Elvira Manzano, 28 Jun 2020

Hyperkalaemia (HK) occurrence and recurrence are frequent in advanced CKD*, creating a perfect storm for cardiovascular events and death, says Professor Juan-Jesus Carrero from the Karolinska Institute, Solna, Sweden, at ERA-EDTA 2020. Given these risks, acutely elevated potassium (K+) should merit clinical attention.